Skip to content
AnalystLens

ARCH CAPITAL GROUP LTD. 8-K/A Report, Executive Changes (Nov 8, 2024)

Reports
Leadership Changes
Filing Date
Filed November 8, 2024
Period End
October 11, 2024
Securities
ACGLACGLNACGLO
In the record · 2016–202610-K1110-Q328-K172

ACGL filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 172 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Nov ’17Nov ’17
  2. Leadership change8-K · Nov ’19Nov ’19
  3. Material agreement8-K · Apr ’22Apr ’22
  4. Material agreement8-K · Jun ’26Jun ’26

Summary

Summary of the 8-K/A filed November 8, 2024. Cited figures are marked; the original filing is the authoritative source.

Arch Capital Group Ltd. (ACGL) has filed an amendment to a previous 8-K report, providing supplemental information regarding its new Chief Executive Officer, Nicolas Papadopoulo.

The amendment confirms Mr. Papadopoulo's appointment as CEO and board member, which was originally disclosed on October 15, 2024. A key update is his appointment to the Executive Committee of the Board, effective November 7, 2024, underscoring his elevated role in strategic decision-making. Furthermore, the filing details a significant "Outperformance Award" granted to Mr. Papadopoulo, comprising premium-priced stock options and time-vested restricted shares, with a total grant date value of $23 milliona.

This award is designed to incentivize long-term performance and aligns with his new leadership position. The structure of the award, including its premium exercise price for options and holding periods for both options and restricted shares, indicates a focus on sustained value creation and executive retention.

Key Highlights

  1. Nicolas Papadopoulo appointed to the Executive Committee of Arch Capital Group's Board of Directors, effective November 7, 2024.
  2. A special "Outperformance Award" has been granted to CEO Nicolas Papadopoulo.
  3. The Outperformance Award has a total grant date value of $23 million.
  4. Seventy percent of the award is in the form of premium-priced stock options, with an exercise price 1.685 times the closing share price on the grant date.
  5. The stock options vest on the third anniversary of the grant date and require a two-year holding period for net shares received upon exercise.
  6. Thirty percent of the award is in the form of time-vested restricted shares, vesting in three equal annual installments.
  7. Restricted shares require a five-year holding period from the grant date, with exceptions for death or change in control.

Frequently Asked Questions

  1. What is the significance of Nicolas Papadopoulo's appointment to the Executive Committee?

    His appointment to the Executive Committee signifies a further elevation of his role within the company's leadership, indicating his direct involvement in key strategic decisions and oversight at the highest level of the board.

  2. What is the "Outperformance Award" and what is its purpose?

    The Outperformance Award is a special equity incentive designed for the new CEO, Nicolas Papadopoulo. It consists of premium-priced stock options and time-vested restricted shares valued at $23 million at grant date. Its purpose is to strongly align Mr. Papadopoulo's interests with long-term shareholder value creation and to incentivize him to achieve superior performance.

  3. What are the key terms of the stock options within the Outperformance Award?

    The stock options have a premium exercise price, set at 1.685 times the company's closing share price on the grant date (November 19, 2024). They fully vest on the third anniversary of the grant date. Upon exercise after vesting, Mr. Papadopoulo must hold the resulting shares for two years, subject to exceptions for death or change in control.

  4. What are the key terms of the restricted shares within the Outperformance Award?

    The restricted shares vest in three equal installments over the first three anniversaries of the grant date. Importantly, Mr. Papadopoulo is required to hold these vested shares until the fifth anniversary of the grant date, with provisions for early release upon death or a change in control of the company.